Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found tolerable and showed signs of efficacy in a real-world cohort.
Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.
Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...
Zacks Investment Research on MSN6d
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite SuccessImmunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback